MRNA

Moderna
Biotechnology · Health Care · as of 2026-11-20
Last close
$195.11
-2.1% on the session
1-year return
+706.9%
+316.2% over six months
Volatility
194.4%
annualized, trailing year
Max drawdown
-34.2%
worst peak to trough, 1y
What the numbers say

Moderna is a biotechnology name in the health care sector. Over the past year it returned +706.9%, against +40.5% over three months and -3.7% over one. It trades 94.3% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 194.4% is very high, position sizing matters more here than the ranking does.

Its worst peak-to-trough decline over the year was -34.2%, and it has traded a median $2.9B a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.17 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#1 of 59
Stronger than 100% of its sector on the momentum profile
Across the whole index#1 of 497

How MRNA scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.

Start a free 7-day trial
Full metrics
1 day-2.1%
1 week-12.7%
1 month-3.7%
3 months+40.5%
6 months+316.2%
1 year+706.9%
12-1 momentum+738.0%
Volatility (1y, annualized)194.4%
Max drawdown (1y)-34.2%
Distance vs 200-day average+94.3%
Return per unit of risk3.64
Median daily dollar volume$2.9B
Free newsletter

Get MRNA when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.